BBIO Stock: Price, Earnings History and SEC Filings
BridgeBio Pharma, Inc. (BBIO) last traded at $74.95, up 5.97% on the latest session and up 13.9% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.42 against an analyst estimate of $-0.60, a beat of 30.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BBIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-0.42 | $-0.60 | +30.00% |
| Jun 2026 | Aug 10, 2026 | $-0.78 | $-0.64 | -21.88% |
| Mar 2026 | May 7, 2026 | $-0.84 | $-0.70 | -20.00% |
| Dec 2025 | Feb 24, 2026 | $-1.00 | $-0.75 | -33.33% |
BBIO beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How BBIO reacts to earnings
Across its last 8 earnings releases, BBIO moved 4.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | +5.97% |
| 2026-08-10 | After close | -1.15% |
| 2026-05-07 | After close | -0.09% |
| 2026-02-24 | After close | -2.59% |
| 2026-01-12 | After close | +2.95% |
| 2025-10-29 | After close | -4.88% |
| 2025-08-05 | After close | -8.94% |
| 2025-04-29 | After close | +5.33% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for BBIO
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 13, 2026Other events, Financial statements and exhibits
- 8-K · Aug 31, 2026Other events, Financial statements and exhibits
- 8-K · Aug 17, 2026Material agreement, Other events, Financial statements and exhibits
- 424B7 · Aug 14, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 22, 2026Other events, Financial statements and exhibits
- 8-K · Jul 2, 2026Material agreement, Unregistered share sale, Bylaw change
Insider filing activity
BBIO insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BBIO news
- What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?Nov 1, 2026 · finance.yahoo.com
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS SaysOct 30, 2026 · finance.yahoo.com
- BridgeBio (BBIO) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- BridgeBio Pharma, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings CallOct 30, 2026 · marketbeat.com
- BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesOct 29, 2026 · finance.yahoo.com
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- BridgeBio Pharma: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.